{
  "id": "56c3184050c68dd416000003",
  "type": "factoid",
  "question": "What is the indication for isradipine?",
  "ideal_answer": "Isradipine is safe and effective when administered long-term in the treatment of hypertensive patients",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/8213473",
    "http://www.ncbi.nlm.nih.gov/pubmed/10728516",
    "http://www.ncbi.nlm.nih.gov/pubmed/8963604",
    "http://www.ncbi.nlm.nih.gov/pubmed/2150641",
    "http://www.ncbi.nlm.nih.gov/pubmed/15257873",
    "http://www.ncbi.nlm.nih.gov/pubmed/8466736",
    "http://www.ncbi.nlm.nih.gov/pubmed/7848351",
    "http://www.ncbi.nlm.nih.gov/pubmed/7918132",
    "http://www.ncbi.nlm.nih.gov/pubmed/14727944",
    "http://www.ncbi.nlm.nih.gov/pubmed/7738211",
    "http://www.ncbi.nlm.nih.gov/pubmed/7789292",
    "http://www.ncbi.nlm.nih.gov/pubmed/2523644",
    "http://www.ncbi.nlm.nih.gov/pubmed/2523646",
    "http://www.ncbi.nlm.nih.gov/pubmed/7921533",
    "http://www.ncbi.nlm.nih.gov/pubmed/7946181",
    "http://www.ncbi.nlm.nih.gov/pubmed/12215829",
    "http://www.ncbi.nlm.nih.gov/pubmed/9544865",
    "http://www.ncbi.nlm.nih.gov/pubmed/2137344",
    "http://www.ncbi.nlm.nih.gov/pubmed/11172743",
    "http://www.ncbi.nlm.nih.gov/pubmed/8205296",
    "http://www.ncbi.nlm.nih.gov/pubmed/2949585",
    "http://www.ncbi.nlm.nih.gov/pubmed/1363224",
    "http://www.ncbi.nlm.nih.gov/pubmed/7621840",
    "http://www.ncbi.nlm.nih.gov/pubmed/10854683",
    "http://www.ncbi.nlm.nih.gov/pubmed/7955262"
  ],
  "snippets": [
    {
      "text": "These are the preliminary data of an open multicenter trial of antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension (WHO classification I or II). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7946181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " It is concluded that isradipine is safe and effective when administered long-term in the treatment of hypertensive patients with either hyperlipidemia or NIDDM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7946181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Regression of left ventricular hypertrophy with isradipine antihypertensive therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466736",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These are the preliminary data of an open multicenter trial of antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension (WHO classification I or II).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7946181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8205296",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "isradipine antihypertensive therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466736",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "isradipine antihypertensive therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Isradipine monotherapy was an effective antihypertensive drug ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137344",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Isradipine is cytoprotective after a stroke when used as an antihypertensive: at doses which normalise high blood pressure in spontaneously hypertensive rats, isradipine reduces by more than 60% the infarct size caused by a subsequent stroke",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2150641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7848351",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "[Isradipine in arterial hypertension in motor vehicle drivers].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8963604",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2523644",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2523646",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "it is advisable to be very careful in the use of isradipine as a therapy for hypertension and other indications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15257873",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Calcium channel antagonists (CCAs) may either be divided into the dihydropyridines (e.g. amlodipine, felodipine, isradipine, lacidipine, nilvadipine, nifedipine, nicardipine etc.), t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727944",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the past few years, however, several dihydropyridine calcium channel antagonists, including nicardipine, isradipine, felodipine, nimodipine, and amlodipine, have been marketed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8213473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137344",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017275",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006973",
    "http://www.biosemantics.org/jochem#4250298",
    "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4250298"
  ],
  "exact_answer": "Hypertension"
}